2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3345 Highly multiplexed detection and quantification of six clinically relevant KMT2A rearrangements in acute leukemias

Dongbin Xu, Ph.D, Yulei Shang, Ph.D2, Vladyslava Ratushna, Ph.D3, Janice Lai, Ph.D4, Arun Nalla, Ph.D5, Bettina Burnworth, Ph.D6, Eleen Shum, Ph.D7, Kelly Li, Ph.D8, Christina Fan, Ph.D9
1 Hematologics, INC.,, Seattle, Washington, United States
2 Countable Labs, Palo Alto, California, United States
3 Countable Labs, Palo Alto, California, United States
4 Countable Labs, Palo Alto, California, United States
5 Hematologics, INC.,, Seattle, Washington, United States
6 Hematologics, INC.,, Seattle, Washington, United States
7 Countable Labs, Palo Alto, California, United States
8 Countable Labs, Palo Alto, California, United States
9 Countable Labs, Palo Alto, California, United States

Background:    KMT2A-rearranged acute leukemias are aggressive subtypes associated with poor prognosis, chemotherapy resistance, and frequent relapse. Although more than 90 KMT2A fusion partners have been reported, a limited number accounts for most clinically relevant cases. Accurate identification of KMT2A fusion transcripts is increasingly important for diagnosis, risk stratification, treatment selection, and measurable residual disease (MRD) monitoring, particularly following the introduction of menin inhibitors. Current molecular methods have limitations: RT-qPCR offers high sensitivity but limited multiplexing, digital PCR provides absolute quantification but restricted multiplexing capacity with limited partition for MRD, and next-generation sequencing enables comprehensive profiling at the expense of longer turnaround time, greater complexity, and higher cost. To meet the unmet needs, we developed a highly multiplexed one-step RT PCR assays for simultaneous detection and absolute quantification of the six most clinically relevant KMT2A rearrangements using single molecular counting on 10-color Countable PCR platform.  Orthogonal testing of leukemia samples showed good concordance.

Methods:  The assays adapte a combinatorial probe-labeling strategy that assigns each fusion transcript a unique optical signature. Six major KMT2A fusion partners (MLLT3/AF9, AFF1/AF4, MLLT4/AFDN(AF6), ELL, MLLT10/AF10, and MLLT1/ENL) and their common breakpoint exons were incorporated, enabling simultaneous detection of 18 clinically relevant KMT2A fusion transcripts from one sample. An ABL1 assay served as an internal reference for RNA quantity and quality assessment and MRD calculation. Analytical performance was evaluated using synthetic DNA (gBlocks), in vitro-transcribed (IVT) RNA, fusion-positive cell-line RNA, and serial dilutions of IVT RNA in HL-60 total RNA. Analytical specificity, sensitivity, linearity, precision, and reproducibility were assessed. Clinical performance was evaluated using 11 AML RNA specimens that were tested on another platform previously.  

Results:  The assay accurately distinguished all 6 targeted KMT2A rearrangements based on their predefined optical signatures. Using IVT RNA, the assay consistently detected as few as 10 fusion transcript copies and demonstrated excellent linearity across multiple orders of magnitude. Absolute transcript counts closely matched expected input levels. Using fusion-positive cell-line RNA, the assay achieved a sensitivity of as low as 0.005% relative to the endogenous ABL transcript, supporting MRD applications. Quantification remained highly reproducible across wide dynamic range, with coefficients of variation below 15% near the lower limit of quantification. Evaluation of 11 clinical specimens showed good concordance with the results from an orthogonal method for KMT2A fusion identification. All three diagnostic samples were tested positive for the expected fusion partners.  Among the eight MRD samples, six tested positive for the expected fusion partners, while the other two samples failed to make a call were due to insufficient sample input, indicated by the low counts of reference ABL assay.  These studies demonstrate both analytical sensitivity and clinical feasibility.

Conclusions:  We developed a highly multiplexed one-step RT Countable PCR assay capable of simultaneously detecting and absolutely quantifying 18 clinically relevant KMT2A fusion transcripts. The assay demonstrated excellent analytical specificity, broad linear dynamic range, robust quantitative precision, and high sensitivity, detecting KMT2A rearrangements down to 0.005% relative to ABL. Initial clinical evaluation showed good concordance with those from orthogonal method for both diagnostic and MRD specimens. This workflow provides a rapid, highly sensitive and specific approach for comprehensive KMT2A fusion detection and quantitative MRD monitoring, supporting its clinical application in AML and other acute leukemias.

 

 

Kelly Li, Ph.D: Countable Labs - Current equity holder in private company; Countable Labs - Current equity holder in private company; Countable Labs - Current Employment; Countable Labs - Current Employment